Roles of Histamine and Its Receptors in Allergic and Inflammatory Bowel Diseases

Total Page:16

File Type:pdf, Size:1020Kb

Roles of Histamine and Its Receptors in Allergic and Inflammatory Bowel Diseases PO Box 2345, Beijing 100023, China World J Gastroenterol 2005;11(19):2851-2857 www.wjgnet.com World Journal of Gastroenterology ISSN 1007-9327 [email protected] © 2005 The WJG Press and Elsevier Inc. All rights reserved. ELSEVIER • REVIEW • Roles of histamine and its receptors in allergic and inflammatory bowel diseases Hua Xie, Shao-Heng He Hua Xie, Shao-Heng He, Allergy and Inflammation Research these diseases. The prevalence of allergy has shown an Institute, Shantou University Medical College, Shantou 515031, increase in the last few years. At present it affects about Guangdong Province, China 30-40% of world population and has become one of the Supported by the Li Ka Shing Foundation, Hong Kong, China, No. st C0200001; the Planned Science and Technology Project of Guangdong three key diseases in the 21 century. Province, China, No. 2003B31502 Since last two decades, inflammation has been known Correspondence to: Professor Shao-Heng He, Allergy and as the main pathophysiological characteristics of allergy. Inflammation Research Institute, Shantou University Medical Mast cells are major participants of allergic reactions, and College, 22 Xin-Ling Road, Shantou 515031, Guangdong Province, their activation may be all that is sufficient and necessary China. [email protected] for the rapid development of microvascular leakage and Telephone: +86-754-8900405 Fax: +86-754-8900192 tissue edema in sensitized subjects exposed to allergen. Received: 2004-04-30 Accepted: 2004-07-15 Mast cell is a key source of potent mediators of allergic inflammation including histamine, neutral proteinases, proteoglycans, prostaglandin D2, leukotriene C4 and certain [1] Abstract cytokines . Among them, histamine is the first mediator implicated in the pathophysiological changes of asthma when Mast cell has a long history of being recognized as an it was found to mimic several features of the disease, and important mediator-secreting cell in allergic diseases, and James received the Nobel Prize for medicine in 1988 for has been discovered to be involved in IBD in last two decades. Histamine is a major mediator in allergic diseases, his outstanding achievements in histamine research. Recently, and has multiple effects that are mediated by specific some novel findings concerning histamine, mast cell and surface receptors on target cells. Four types of histamine allergy or IBD have been reported and are summarized receptors have now been recognized pharmacologically herein. and the first three are located in the gut. The ability of histamine receptor antagonists to inhibit mast cell THE ROLES OF MAST CELLS IN ALLERGIC degranulation suggests that they might be developed as a group of mast cell stabilizers. Recently, a series of DISEASES experiments with dispersed colon mast cells suggested Mast cell has a long history of being recognized as an that there should be at least two pathways in man for important mediator-secreting cell in allergic diseases. It has mast cells to amplify their own activation-degranulation a high capacity to release an array of both preformed and signals in an autocrine or paracrine manner. In a word, histamine is an important mediator in allergic diseases newly generated mediators in response to environmental and IBD, its antagonists may be developed as a group of stimuli, especially allergen exposure. Cross linkage of IgE mast cell stabilizers to treat these diseases. bound to high affinity receptors on mast cells not only results in the rapid release of autacoid mediators, but also the © 2005 The WJG Press and Elsevier Inc. All rights reserved. sustained synthesis and release of cytokines, chemokines and growth factors. Key words: Allergic diseases; Immunoglobulin Mature mast cells are ubiquitous in human tissues and can thus participate in the processes of inflammation at Xie H, He SH. Roles of histamine and its receptors in allergic different sites. Systemic anaphylaxis, a life-threatening disease, and inflammatory bowel diseases. World J Gastroenterol involves mast cell activation in multiple organs. In bronchial 2005; 11(19): 2851-2857 asthma, a disease characterized by widespread but potentially http://www.wjgnet.com/1007-9327/11/2851.asp reversible bronchial obstruction, there are increased numbers of mast cells and a greater degree of continuous mast cell degranulation in bronchoalveolar lavage fluid from asthmatics compared with normal controls. Increased mast cell numbers INTRODUCTION and evidence for continuous degranulation of mast cells Allergic diseases including allergic asthma, allergic rhinitis, have been observed also in nasal lavage fluid and the nasal food allergy, drug allergy, and allergic atopic eczema/dermatitis epithelium of the patients with allergic rhinitis. syndrome, etc. are a group of common disorders which are Recent population surveys have estimated rates of regarded to be mediated by immunoglobulin (Ig) E. People prevalence of perceived food hypersensitivity of 12-20% at all ages in countries throughout the world suffer from in adults though this rate varied largely across different 2852 ISSN 1007-9327 CN 14-1219/ R World J Gastroenterol May 21, 2005 Volume 11 Number 19 countries (e.g. Spain, 4.6%; Australia, 19.1%) despite a histamine metabolism was found in collagenous colitis and common standardized methodology[2]. Intestinal mast cells, food allergy[8], and increased level of N-methylhistamine, a as well as eosinophils, have been shown to be involved in stable metabolite of the mast cell mediator histamine, was the pathogenesis of food-allergy-related enteropathy. detected in the urine of patients with active Crohn’s Adverse drug reactions are common, but only 6-10% disease or ulcerative colitis[9,10]. Since increased level of N- are immunologically mediated[3]. Although allergic drug methylhistamine was significantly correlated to clinical disease reactions are just one type of adverse reactions to medications, activity, the above findings further strongly suggest the active they are clinically very important because of the morbidity involvement of histamine in the pathogenesis of these diseases. and mortality they cause. Allergic drug reactions may result Interestingly, mast cells originated from the resected in anaphylaxis, urticaria, bronchospasm and angioedema. colon of active Crohn’s disease or ulcerative colitis were During these reactions, allergic drugs cause direct histamine able to release more histamine than those from normal release from mast cells. colon when being stimulated with an antigen, colon-derived murine epithelial cell-associated compounds[11]. Similarly, cultured colorectal endoscopic samples from patients with THE ROLES OF HISTAMINE IN ALLERGIC IBD secreted more histamine towards substance P alone DISEASE or substance P with anti-IgE than the samples from normal control subjects under the same stimulation[12]. In a guinea Since its discovery in 1911, histamine has been recognized pig model of intestinal inflammation induced by cow’s milk as a major mediator in allergic diseases. Histamine is a proteins and trinitrobenzene sulfonic acid, both IgE titers primary amine synthesized from histidine in the Golgi and histamine levels were higher than normal control apparatus, from where it is transported to the granule for animals[13]. storage in ionic association with the acidic residues of the As a proinflammatory mediator, histamine is selectively glycosaminoglycans side chains of heparin and with located in the granules of human mast cells and basophils proteinases. The histamine content of mast cells dispersed and released from these cells upon degranulation. To date, from human lung and skin is similar at 2-5 pg/cell, and the a total of three histamine receptors H1, H2 and H3 have histamine stored ranges from 10 to 12 µg/g in both tissues. been discovered in human gut[14,15]. It proves that there are Following mast cell activation, histamine is rapidly dissociated some specific targets that histamine can work on in intestinal from the granule matrix by exchange with sodium ions in tract. Histamine was found to cause a transient concentration- the extracellular environment. Proteoglycans comprise the dependent increase in short-circuit current, a measure of total major supporting matrix of the mast cell granule with the ion transport across the epithelial tissue in the gut[16]. This sulfate groups binding to histamine, proteinases and acid could be due to that histamine interacts with H1 receptors hydrolases. As only mast cells and basophils contain to increase the secretion of Na and Cl ions from epithelium[17]. histamine in man (apart from histaminergic nerve), and there The finding that H1-receptor antagonist pyrilamine was are few basophils in human tissues, histamine can be used able to inhibit anti-IgE induced histamine release and ion as a marker of mast cell degranulation. transport[18] suggested further that histamine is a crucial The allergic process is believed to consist of two phases: mediator responsible for diarrhea in IBD and food allergy. early and late. The early phase reaction is mainly induced The ability of SR140333, a potent NK1 antagonist in reducing by histamine released from mast cells. Histamine is a potent mucosal ion transport, was most likely due to its inhibitory vasoactive agent, bronchial smooth muscle constrictor, and actions on histamine release from colon mast cells[19]. stimulant of nociceptive itch nerves. In addition to its known effects on glands, vessels and sensory nerves, recent data have provided further evidence of
Recommended publications
  • Product List March 2019 - Page 1 of 53
    Wessex has been sourcing and supplying active substances to medicine manufacturers since its incorporation in 1994. We supply from known, trusted partners working to full cGMP and with full regulatory support. Please contact us for details of the following products. Product CAS No. ( R)-2-Methyl-CBS-oxazaborolidine 112022-83-0 (-) (1R) Menthyl Chloroformate 14602-86-9 (+)-Sotalol Hydrochloride 959-24-0 (2R)-2-[(4-Ethyl-2, 3-dioxopiperazinyl) carbonylamino]-2-phenylacetic 63422-71-9 acid (2R)-2-[(4-Ethyl-2-3-dioxopiperazinyl) carbonylamino]-2-(4- 62893-24-7 hydroxyphenyl) acetic acid (r)-(+)-α-Lipoic Acid 1200-22-2 (S)-1-(2-Chloroacetyl) pyrrolidine-2-carbonitrile 207557-35-5 1,1'-Carbonyl diimidazole 530-62-1 1,3-Cyclohexanedione 504-02-9 1-[2-amino-1-(4-methoxyphenyl) ethyl] cyclohexanol acetate 839705-03-2 1-[2-Amino-1-(4-methoxyphenyl) ethyl] cyclohexanol Hydrochloride 130198-05-9 1-[Cyano-(4-methoxyphenyl) methyl] cyclohexanol 93413-76-4 1-Chloroethyl-4-nitrophenyl carbonate 101623-69-2 2-(2-Aminothiazol-4-yl) acetic acid Hydrochloride 66659-20-9 2-(4-Nitrophenyl)ethanamine Hydrochloride 29968-78-3 2,4 Dichlorobenzyl Alcohol (2,4 DCBA) 1777-82-8 2,6-Dichlorophenol 87-65-0 2.6 Diamino Pyridine 136-40-3 2-Aminoheptane Sulfate 6411-75-2 2-Ethylhexanoyl Chloride 760-67-8 2-Ethylhexyl Chloroformate 24468-13-1 2-Isopropyl-4-(N-methylaminomethyl) thiazole Hydrochloride 908591-25-3 4,4,4-Trifluoro-1-(4-methylphenyl)-1,3-butane dione 720-94-5 4,5,6,7-Tetrahydrothieno[3,2,c] pyridine Hydrochloride 28783-41-7 4-Chloro-N-methyl-piperidine 5570-77-4
    [Show full text]
  • A Comparative Evaluation of Lafutidine and 2 Rabeprazole in The
    1 *Original research paper 2 A comparative evaluation of Lafutidine and 3 Rabeprazole in the treatment of gastritis and 4 peptic ulcer: A double-blind, randomized study 5 in Indian patients. 6 Dr. Sanjay Kumar 1, Dr. Bhupesh Dewan 2*, Deepashri Shah 2 7 8 1Global Liver and Gastroenterology Centre, Bhopal, India 2 9 Medical Department, Zuventus Healthcare Ltd., Mumbai, India 10 11 . 12 ABSTRACT 13 Aims: To assess the efficacy of lafutidine therapy versus rabeprazole in Indian patients with endoscopically and histologically proven gastritis and peptic ulcer. Study design: A double blind, double dummy, randomized, comparative study. Place and Duration of Study: Global Liver and Gastroenterology Centre, Bhopal, India, between March 2010 and October 2010. Methodology: A total of 100 patients were enrolled, including 50 with endoscopically and histologically proven gastritis and other 50 with peptic ulcer (over 5 mm in diameter). Each group was randomized to receive either lafutidine or rabeprazole tablet and their corresponding competitor placebo dummy tablet, for a period of 4 weeks. Gastritis/ulcer cure rates confirmed by endoscopic histology, symptom response and Helicobacter pylori (H. Pylori) eradication were compared among the two drugs Results: Complete cure of gastritis was observed in all the patients (100%) treated with lafutidine and 95.24% [20/21; 95% CI: 76.18 to 99.88%] patients treated with rabeprazole. Complete cure of ulcer was observed in 72.0% (18/25, 95% CI = 50.61 to 87.93%) and 79.16% (19/24, 95% CI = 57.85 to 92.87%) patients treated with lafutidine and rabeprazole respectively. There was no significant difference in gastritis/ulcer cure rate and symptom response rate between the two treatment groups at the end of the study.
    [Show full text]
  • Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis
    International Journal of Molecular Sciences Article Histamine H2-Receptor Antagonists Improve Non-Steroidal Anti-Inflammatory Drug-Induced Intestinal Dysbiosis Rei Kawashima, Shun Tamaki, Fumitaka Kawakami, Tatsunori Maekawa and Takafumi Ichikawa * Department of Regulation Biochemistry, Kitasato University Graduate School of Medical Sciences, Kanagawa 252-0374, Japan; [email protected] (R.K.); [email protected] (S.T.); [email protected] (F.K.); [email protected] (T.M.) * Correspondence: [email protected]; Tel.: +81-42-778-8863 Received: 8 October 2020; Accepted: 30 October 2020; Published: 31 October 2020 Abstract: Dysbiosis, an imbalance of intestinal flora, can cause serious conditions such as obesity, cancer, and psychoneurological disorders. One cause of dysbiosis is inflammation. Ulcerative enteritis is a side effect of non-steroidal anti-inflammatory drugs (NSAIDs). To counteract this side effect, we proposed the concurrent use of histamine H2 receptor antagonists (H2RA), and we examined the effect on the intestinal flora. We generated a murine model of NSAID-induced intestinal mucosal injury, and we administered oral H2RA to the mice. We collected stool samples, compared the composition of intestinal flora using terminal restriction fragment length polymorphism, and performed organic acid analysis using high-performance liquid chromatography. The intestinal flora analysis revealed that NSAID [indomethacin (IDM)] administration increased Erysipelotrichaceae and decreased Clostridiales but that both had improved with the concurrent administration of H2RA. Fecal levels of acetic, propionic, and n-butyric acids increased with IDM administration and decreased with the concurrent administration of H2RA. Although in NSAID-induced gastroenteritis the proportion of intestinal microorganisms changes, leading to the deterioration of the intestinal environment, concurrent administration of H2RA can normalize the intestinal flora.
    [Show full text]
  • Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Cr
    Drug Name Plate Number Well Location % Inhibition, Screen Axitinib 1 1 20 Gefitinib (ZD1839) 1 2 70 Sorafenib Tosylate 1 3 21 Crizotinib (PF-02341066) 1 4 55 Docetaxel 1 5 98 Anastrozole 1 6 25 Cladribine 1 7 23 Methotrexate 1 8 -187 Letrozole 1 9 65 Entecavir Hydrate 1 10 48 Roxadustat (FG-4592) 1 11 19 Imatinib Mesylate (STI571) 1 12 0 Sunitinib Malate 1 13 34 Vismodegib (GDC-0449) 1 14 64 Paclitaxel 1 15 89 Aprepitant 1 16 94 Decitabine 1 17 -79 Bendamustine HCl 1 18 19 Temozolomide 1 19 -111 Nepafenac 1 20 24 Nintedanib (BIBF 1120) 1 21 -43 Lapatinib (GW-572016) Ditosylate 1 22 88 Temsirolimus (CCI-779, NSC 683864) 1 23 96 Belinostat (PXD101) 1 24 46 Capecitabine 1 25 19 Bicalutamide 1 26 83 Dutasteride 1 27 68 Epirubicin HCl 1 28 -59 Tamoxifen 1 29 30 Rufinamide 1 30 96 Afatinib (BIBW2992) 1 31 -54 Lenalidomide (CC-5013) 1 32 19 Vorinostat (SAHA, MK0683) 1 33 38 Rucaparib (AG-014699,PF-01367338) phosphate1 34 14 Lenvatinib (E7080) 1 35 80 Fulvestrant 1 36 76 Melatonin 1 37 15 Etoposide 1 38 -69 Vincristine sulfate 1 39 61 Posaconazole 1 40 97 Bortezomib (PS-341) 1 41 71 Panobinostat (LBH589) 1 42 41 Entinostat (MS-275) 1 43 26 Cabozantinib (XL184, BMS-907351) 1 44 79 Valproic acid sodium salt (Sodium valproate) 1 45 7 Raltitrexed 1 46 39 Bisoprolol fumarate 1 47 -23 Raloxifene HCl 1 48 97 Agomelatine 1 49 35 Prasugrel 1 50 -24 Bosutinib (SKI-606) 1 51 85 Nilotinib (AMN-107) 1 52 99 Enzastaurin (LY317615) 1 53 -12 Everolimus (RAD001) 1 54 94 Regorafenib (BAY 73-4506) 1 55 24 Thalidomide 1 56 40 Tivozanib (AV-951) 1 57 86 Fludarabine
    [Show full text]
  • Jp Xvii the Japanese Pharmacopoeia
    JP XVII THE JAPANESE PHARMACOPOEIA SEVENTEENTH EDITION Official from April 1, 2016 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the convenience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 64 Pursuant to Paragraph 1, Article 41 of the Law on Securing Quality, Efficacy and Safety of Products including Pharmaceuticals and Medical Devices (Law No. 145, 1960), the Japanese Pharmacopoeia (Ministerial Notification No. 65, 2011), which has been established as follows*, shall be applied on April 1, 2016. However, in the case of drugs which are listed in the Pharmacopoeia (hereinafter referred to as ``previ- ous Pharmacopoeia'') [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as ``new Pharmacopoeia'')] and have been approved as of April 1, 2016 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as of March 31, 2016 as those exempted from marketing approval pursuant to Paragraph 1, Article 14 of the Same Law (hereinafter referred to as ``drugs exempted from approval'')], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on September 30, 2017.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Use of Proton Pump Inhibitors and Subsequent Risk of Celiac Disease
    Digestive and Liver Disease 46 (2014) 36–40 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Alimentary Tract Use of proton pump inhibitors and subsequent risk of celiac disease Benjamin Lebwohl a,b, Stuart J. Spechler c, Timothy C. Wang a, Peter H.R. Green a, Jonas F. Ludvigsson b,d,∗ a Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA b Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden c Division of Gastroenterology, Department of Internal Medicine, VA North Texas Healthcare System and UT Southwestern Medical Center, Dallas, TX, USA d Department of Pediatrics, Örebro University Hospital, Sweden article info abstract Article history: Background: The prevalence of celiac disease and the use of medications that inhibit acid secretion have Received 14 May 2013 both increased in recent decades. Accepted 6 August 2013 Aim: To explore the association between antisecretory medication exposure and subsequent development Available online 12 September 2013 of celiac disease. Methods: In this population-based case control study, we identified patients with celiac disease diagnosed Keywords: at all pathology departments in Sweden from July 2005 through February 2008. Patients were matched Celiac disease by age and gender with up to 5 controls. We identified prior prescriptions for proton pump inhibitors Proton pump inhibitors Risk factors and histamine-2 receptor antagonists in all subjects. We used conditional logistic regression to measure the association between these prescriptions and the subsequent diagnosis of celiac disease. Results: Prior proton pump inhibitor prescription was strongly associated with celiac disease (OR 4.79; 95% CI 4.17–5.51).
    [Show full text]
  • Effectiveness and Tolerability of Different Recommended Doses Of
    www.nature.com/scientificreports OPEN Effectiveness and Tolerability of Different Recommended Doses of PPIs and H2RAs in GERD: Network Received: 26 April 2016 Accepted: 15 December 2016 Meta-Analysis and GRADE system Published: 19 January 2017 Chao Zhang1, Joey S. W. Kwong2, Rui-Xia Yuan1,3, Hao Chen4, Chang Xu5, Yi-Pin Wang1, Gong-Li Yang6, Jin-Zhu Yan1, Le Peng1, Xian-Tao Zeng1, Hong Weng1, Jie Luo1 & Yu-Ming Niu1,6 Proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RAs) are used for gastro- esophageal reflux disease (GERD); however, the clinical evidence for treatment is poor. We evaluated the effectiveness and tolerability of different doses of PPIs,2 H RAs and placebo in adults with GERD. Six online databases were searched through September 1, 2016. All related articles were included and combined with a Bayesian network meta-analysis from randomized controlled trials (RCTs). The GRADE systems were employed to assess the main outcome. Ninety-eight RCTs were identified, which included 45,964 participants. Our analysis indicated that the full/standard dose of esomeprazole at 40 mg per day was the most efficient in healing among nine different dosages of PPIs and2 H RAs. The main efficacy outcome did not change after adjustments for the area, age, level of disease from endoscopy, year of publication, pharmaceutical industry sponsorship, Intention-to-treat (ITT)/per-protocol (PP), withdrawal rate, pre-set select design bias, single blinded and unblinded studies, study origination in China, study arms that included zero events, inconsistency node or discontinued drug were accounted for in the meta-regressions and sensitivity analyses.
    [Show full text]
  • Feasibility Study of Supportive Care Using Lafutidine, a Histamine H2 Receptor Antagonist, to Prevent Gastrointestinal Toxicity During Chemotherapy for Gastric Cancer
    ANTICANCER RESEARCH 34: 7297-7302 (2014) Feasibility Study of Supportive Care Using Lafutidine, a Histamine H2 Receptor Antagonist, to Prevent Gastrointestinal Toxicity During Chemotherapy for Gastric Cancer TSUTOMU NAMIKAWA1, ERI MUNEKAGE1, HIROMICHI MAEDA2, HIROYUKI KITAGAWA1, MICHIYA KOBAYASHI1 and KAZUHIRO HANAZAKI1 1Department of Surgery, and 2Cancer Treatment Center, Kochi Medical School, Kochi, Japan Abstract. The present study evaluated the efficacy of Gastric cancer is the third most common cancer and the second lafutidine, a histamine H2 receptor antagonist, for reducing most common cause of cancer-related death worldwide. It is gastrointestinal toxicities during adjuvant chemotherapy also the most common malignancy in Asia, South America, and using oral fluorouracil anticancer drugs for gastric cancer. Eastern Europe (1). Based on results from the Adjuvant Patients and Methods: Patients with stage II (T1 cases Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC), excluded) or stage III gastric adenocarcinoma who postoperative administration of S-1 for one year is now underwent gastrectomy with D2 lymphadenectomy achieving considered the standard adjuvant treatment for curatively R0 resection from 2011 to 2013 were prospectively enrolled resected stage II/III gastric cancer in Japan (2). S-1 is an oral in the study. Patients were randomly assigned to either S-1 anticancer drug that combines the pro-fluorouracil drug tegafur, treatment or S-1 plus lafutidine treatment. Quality of life an inhibitor of dihydropyrimidine dehydrogenase, and and gastrointestinal toxicity were evaluated before potassium oxonate, in a molar ratio of 1:0.4:1. However, chemotherapy and at 2, 4, and 6 weeks after the beginning treatment with S-1 was continued for at least three months in of treatment.
    [Show full text]
  • Ranitidine Protocol – Final Confidential Version 1.0 – 17Th January 2020 PASS Information
    RANITIDINE AND OTHER HISTAMINE-H2-RECEPTOR ANTAGONISTS – A DRUG UTILISATION STUDY Principal Investigators Katia Verhamme, MD, PhD Department of Medical Informatics EMC – Rotterdam Peter Rijnbeek, PhD Department of Medical Informatics EMC - Rotterdam Document Status Final Version 1.0 Date of final version of the study 17th January 2020 report EU PAS register number 1 EMA TENDER – Ranitidine protocol – Final Confidential Version 1.0 – 17th January 2020 PASS information Title Ranitidine and other histamine H2-receptor antagonists – a drug utilisation study Protocol version identifier V1.0 Final Date of last version of protocol 2020-01-17 EU PAS register number Active Ingredient Ranitidine Cimetidine Famotidine Nizatidine Niperotidine Roxatidine Ranitidine bismuth citrate Lafutidine Medicinal product Ranitidine Product reference Procedure number Marketing authorisation holder(s) Joint PASS Research question and objectives Ranitidine is a competitive and reversible inhibitor of the action of histamine and indicated for the management of peptic ulceration, Gastro-Esophageal Reflux Disease (GERD), reflux oesophagitis and Zollinger-Ellison syndrome. Results of a preliminary laboratory analysis have shown the presence of N-Nitrosodimethylamine (NDMA), a human carcinogen, in ranitidine. With this DUS, we aim to determine drug utilisation and prescription patterns of medicinal products containing H2-receptor antagonists. These data will give insight on the number of patients using ranitidine and thus potentially at risk of NDMA. In particular we will: 1. Study the prevalence and incidence prescribing of H2-receptor antagonists as a class and by individual drug 2 EMA TENDER – Ranitidine protocol – Final Confidential Version 1.0 – 17th January 2020 2. Explore the characteristics of H2-receptor antagonist use with regard to age (10-years age categories), sex, formulation, daily dose, duration and cumulative exposure by class level and individual ingredient 3.
    [Show full text]
  • Developement and Characterization of Floating Tablets of Nizatidine for Peptic Ulcer
    Journal of Advances in Medical and Pharmaceutical Sciences 21(4): 1-12, 2019; Article no.JAMPS.46917 ISSN: 2394-1111 Developement and Characterization of Floating Tablets of Nizatidine for Peptic Ulcer 1 1 2 Sunil T. Galatage , Suresh G. Killedar , Rushikesh B. Katakar , 3* 3 4 Ravindra B. Kumbhar , Maya Sharma and Pramodkumar J. Shirote 1Sant Gajanan Maharaj College of Pharmacy, Mahagaon - 416502, Maharashtra, India. 2Executive Quality Assurance, Shree Anand Life Sciences Ltd., Belgavi, Karnataka, India. 3Department of Pharmacy, Pacific Academy of Higher Education and Research University, Udaipur, Rajasthan, India. 4Arvind Gavali College of Pharmacy, Jaitapur, Satara, India. Authors’ contributions This work was carried out in collaboration among all authors. Authors Ravindra B. Kumbhar and MS designed the study, performed the statistical analysis, wrote the protocol. Authors STG and SGK wrote the first draft of the manuscript. Author PJS and managed the analyses of the study. Author Rushikesh B. Katakar managed the literature search and above all mentioned authors read and approved the final manuscript. All authors read and approved the final manuscript. Article Information DOI: 10.9734/JAMPS/2019/v21i430146 Editor(s): (1) Dr. Hamdy A. Sliem, Professor, Internal Medicine, Suez Canal University, Egypt and College of Dentistry, Qassim University and AL-Jouf University, Saudi Arabia. Reviewers: (1) Vijay Sharma, IFTM University, India. (2) Syed Umer Jan, University of Balochistan, Pakistan. (3) Lombardo Lucio, University of Turin, Italy. Complete Peer review History: http://www.sdiarticle4.com/review-history/46917 Received 15 March 2019 Accepted 21 May 2019 Original Research Article Published 17 January 2020 ABSTRACT The objective of the present research work is to develop an ideal floating drug delivery system of nizatidine to increase the gastric residence time in stomach.
    [Show full text]
  • New and Future Drug Development for Gastroesophageal Reflux Disease
    J Neurogastroenterol Motil, Vol. 20 No. 1 January, 2014 pISSN: 2093-0879 eISSN: 2093-0887 http://dx.doi.org/10.5056/jnm.2014.20.1.6 JNM Journal of Neurogastroenterology and Motility Review New and Future Drug Development for Gastroesophageal Reflux Disease Carla Maradey-Romero and Ronnie Fass* The Esophageal and Swallowing Center, Division of Gastroenterology and Hepatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA Medical therapy remains the most popular treatment for gastroesophageal reflux disease (GERD). Whilst interest in drug devel- opment for GERD has declined over the last few years primarily due to the conversion of most proton pump inhibitor (PPI)’s to generic and over the counter compounds, there are still numerous areas of unmet needs in GERD. Drug development has been focused on potent histamine type 2 receptor antagonist’s, extended release PPI’s, PPI combination, potassium-competitive acid blockers, transient lower esophageal sphincter relaxation reducers, prokinetics, mucosal protectants and esophageal pain modulators. It is likely that the aforementioned compounds will be niched for specific areas of unmet need in GERD, rather than compete with the presently available anti-reflux therapies. (J Neurogastroenterol Motil 2014;20:6-16) Key Words Erosive esophagitis; Gastroesophageal reflux; Heartburn; Proton pump inhibitors Most patients with GERD fall into 1 of 3 categories: non- erosive reflux disease (NERD), erosive esophagitis (EE), and Introduction Barrett’s esophagus (BE). The 2 main phenotypes of GERD, Gastroesophageal reflux disease (GERD) is a common con- NERD and EE, appear to have different pathophysiological and dition that develops when reflux of stomach contents cause trou- clinical characteristics.
    [Show full text]